Merck makes circular RNA play with $3.5bn Orna alliance
Merck & Co has ramped up its involvement in the RNA category, partnering with US biotech Orna Therapeutics in a deal valued at up to […]
R&D
Lipid Nanoparticles Immunogenicity & Toxicity | December 6-8, 2022
Following the success of LNP-mRNA vaccines, we have seen an influx of novel types of lipids based nanocarriers over the last 12 months, progress has been […]
Lipid Nanoparticles Development Summit Europe | 18th – 20th October, 2022
The LNP Development Europe Summit is the only European conference solely dedicated to LNP formulation and process development to enable seamless scale-up, keeping GMP compliance and manufacturing. Given the rapid developments in the […]
Survival data firms up Trodelvy prospects in new breast cancer use
In the space of a couple of months, Gilead Sciences’ Trodelvy impact on overall survival (OS) in the TROPICs-02 trial in advanced breast cancer has […]
Challenges and opportunities in the off-patent sector: the pharmaphorum podcast
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock welcomes Rebecca Guntern, vice president of medicines for Europe at Sandoz. Rebecca speaks about […]
Abecma hits the mark in earlier-stage multiple myeloma
Bristol-Myers Squibb is on course to move its BCMA-targeting CAR-T therapy further up the treatment pathway in multiple myeloma, after reporting that it met its […]
How Pharmacogenomics may finally realise its promise
More than 60 percent of all American adults take prescription drugs, amounting to approximately 131 million individuals. These drugs have been rigorously tested by regulatory […]
BMS adds to IBD pipeline with $1.9bn GentiBio deal
Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for inflammatory bowel disease (IBD). The deal includes […]
Verona cues up filings for COPD drug after it aces phase 3 test
UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory […]
Tagrisso paired with Hutchmed drug clears lung cancer test
EGFR inhibitors like AstraZeneca’s Tagrisso have been hugely successful in treating EGFR-positive lung cancer, but the durability of treatment is often reduced by resistance mutations. […]
AI tissue analysis enables rapid discovery of drug candidates
AI could address the most significant issue in drug discovery, finds Ben Hargreaves, and also offers the potential to use tissue samples to create precision […]
Karuna Therapeutics scores phase 3 win for schizophrenia therapy KarXT
Karuna Therapeutics has unveiled positive topline results from its phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT […]
Sosei Heptares banks $30m milestone in Neurocrine Bio alliance
Sosei Heptares has taken another of its partnered G protein-coupled receptor (GPCR) programmes into mid-stage clinical trials, earning a $30 million milestone payment from Neurocrine […]
Traditional approaches to growth in biopharma are no longer sustainable
Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. Such inorganic growth is no […]
Gilead snaps up MiroBio and its checkpoint agonists for $405m
Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a takeover by Gilead Sciences in a $405 […]
Amgen splashes out on ChemoCentryx and its blockbuster hopeful
Ten months after ChemoCentryx scored an unexpected FDA approval for autoimmune disease therapy Tavneos, Amgen has swooped in with a $3.7 billion bid to buy […]
Pfizer takes pipeline blow as it abandons cardiomyopathy drug
Pfizer has stopped development of a drug to treat cardiomyopathy caused by a rare form of heart disease, after it proved ineffective in a phase […]
Keytruda fluffs its lines in prostate, liver cancer trials
Two phase 3 trials of Merck & Co’s Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver cancer have ended in failure, proving once […]
Roche adds to pipeline with Poseida, Kiniksa deals
Roche has announced a pair of licensing deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that bolster its pipeline in cancer and inflammatory diseases. The agreement […]
Chinese biotech Sironax raises $200m for RIPK1 pipeline
Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors […]
Connecting EHR to clinical trials: How to embrace the promise of real-world data
We all know that real-world data (RWD) from electronic health records (EHR) could boost clinical trial efficiency and improve patient outcomes – so what’s holding […]
Phase 3 lung cancer fail dents prospects of Ipsen, Servier’s Onivyde
Ipsen and Servier’s hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a failed phase 3 trial of the drug […]
AC Immune tries to resurrect crenezumab with new data delve
In May, another amyloid targeting drug for Alzheimer’s disease – AC Immune and Roche’s crenezumab – missed the mark in another clinical trial and looked […]
BMS’ plan to move Opdivo into adjuvant RCC gets knocked back
Bristol-Myers Squibb has revealed that its checkpoint inhibitor combination of Opdivo and Yervoy failed a phase 3 trial as adjuvant (post-surgery) therapy for renal cell […]
Ionis antithrombotic with reduced bleed risk clears phase 2b study
Patients with end-stage renal disease (ESRD) who are on dialysis often need to be treated with anticoagulants to prevent blood clots, but as a result, […]
Boehringer, Seqster team-up on patient-centric, real-world studies
Seqster has attracted another pharma partner for its patient data technology, which aims to improve care through better access and understanding of patient-level real-world data […]
Labcorp unveils plan to spin out clinical development business
Laboratory Corp of America (Labcorp) has announced that it plans to separate its clinical development business into an independent, publicly-traded contract research organisation (CRO). The […]
Welcome to the 6th Complement-based Drug Development Summit 2022
Decipher Complement Pathway Intricacies, Validate Pathway Activation Assays & Discover Next-Generation Complement-Targeted Approaches that are Transforming Patient Outcomes With promising clinical data, an increasing number […]
Pfizer heading for purple patch of in-house product launches
With record-breaking revenues and profits accruing on the back of its COVID-19 products, Pfizer is planning a big spend on business development – but chief […]
Pfizer takes COVID jab with ‘enhanced’ spike protein into phase 2
Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that […]
Healthware forms new medical communications division
Health innovation and technology specialist Healthware Group has added another element to its business with the launch of a dedicated medical communications and education division. […]
The continued search for a cure to HIV
Not very long ago, contracting HIV was an effective death sentence; today, there are treatments that allow the condition to be managed but not eradicated. […]
VistaGen’s horizons may shrink after clinical trial setback
Shares in VistaGen Therapeutics have plummeted after the company reported that its lead pherine nasal spray candidate failed the first of two phase 3 trials […]
Report finds UK risks falling behind rivals in life sciences
A just-published report on the UK’s life sciences sector “ought to ring alarm bells across government,” according to the Association of the British Pharmaceutical Industry […]
Ex-GSK vaccine chief to lead new UK biotech Vicebio
GSK’s former head of vaccines R&D – Dr Emmanuel Hanon – is heading up a new biotech called Vicebio that will go up against his […]
Bid to expand Keytruda use in head and neck cancer therapy fails
While immunotherapies have transformed treatment of many types of cancer, they do sometimes fail to have an impact – as Merck & Co has just […]
CAMP4 raises $100m to take lead RNA drugs into clinic
Armed with a $100 million second-round financing, CAMP4 Therapeutics is preparing to start the first clinical trial of a drug targeting regulatory RNA (regRNA) molecules […]
UK scientists say they have found cancer driver in junk DNA
It has suspected for many years that some diseases may be linked to non-coding or ‘junk’ DNA, but the mechanism behind the pathology hasn’t been […]
Cancer Research UK partnership aims to back 10 new startups
Cancer Research UK has expanded an alliance with investment group Deep Science Ventures with a commitment to support the formation up to 10 new oncology […]
Disappointment as Lynparza fails colorectal cancer test
AstraZeneca and Merck’s PARP inhibitor Lynparza has carved out blockbuster revenues across uses in breast, ovarian, prostate and pancreatic cancer, but colorectal cancer won’t be […]
CanSinoBIO developed a highly effective COVID vaccine with an inhalant version
Pierre A. Morgon, PharmD, LL.M, MBA, managing director at CanSino Biologics Europe, tells us about Convidecia, a single dose SARS-CoV-2 vaccine offered as an injectable […]
Ophthalmic Drugs Conference
SAE Media Group’s 5th Annual Ophthalmic Drugs Conference 21 – 22 November 2022 | London, UK http://www.ophthalmicdrugs.com/PharmaPhorum Delving into advanced R&D and Delivery of Ocular […]
Kyowa Kirin drops Nourianz follow-up KW-6356 for Parkinson’s
Despite reporting proof-of-concept results in a mid-stage trial, Kyowa Kirin has decided to discontinue development of its Parkinson’s disease candidate KW-6356, a drug in the […]
Preventing the next pandemic: Infrastructure and global equity
In the final piece of a three-part series, Ben Hargreaves explores how manufacturing infrastructure was rapidly built up to the required capacity to ensure sufficient […]
EMA pilot will see if clinical trial data should be digested ‘raw’
A pilot study has been launched by the EMA to see whether it is helpful for regulators to look at the ‘raw data’ from clinical […]
Merck buys into Orion prostate cancer therapy in $290m deal
Merck & Co has added another clinical-stage drug to its oncology pipeline via a licensing agreement with Finland’s Orion for ODM-208, a prostate cancer candidate […]
For neurological disease, solving measurement is the first and biggest hurdle to re-imagining treatment
Neurodegenerative diseases like Parkinson’s and Alzheimer’s affect millions of people worldwide, and their prevalence is only increasing, according to the World Health Organization. And while […]
Verve starts trials of cholesterol drug in test of base editing technique
Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off […]
Roche rings Bicycle bell again, grabbing another cancer target
Roche’s Genentech unit has gone all in on its collaboration with UK biotech Bicycle Therapeutics, taking up an option on a second additional target in […]
NIH starts trial of Moderna’s mRNA Nipah virus vaccine
Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection caught from animals that has a fatality […]
Vertex buys diabetes cell therapy rival ViaCyte for $320m
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development […]
Novo Nordisk’s concizumab hits mark in haemophilia, but dosing questioned
Novo Nordisk has reported phase 3 results with its concizumab drug for haemophilia A or B, showing efficacy in the prevention of bleeding events that […]
Sanofi trumpets data with haemophilia treatment duo at ISTH
Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs and gene therapies – and highlighted results […]
AbbVie cuts Alzheimer’s alliance with Alector in half
AbbVie is pulling out of its collaboration with Alector on the development of Alzheimer’s disease candidate AL003, which aims to tackle the neurodegenerative disease by […]
Former Theranos COO Sunny Balwani convicted of fraud
The sorry saga of Theranos continues with the conviction of Ramesh ‘Sunny’ Balwani, the blood testing biotech’s former chief operating officer, for fraud. Balwani (57) […]
Preventing the next pandemic: Supporting early-stage R&D
In the second of a three-part series, Ben Hargreaves looks at the importance of early-stage research into various emerging infectious disease threats and how it […]
Myocarditis case mars Sarepta DMD gene therapy readout
New data on Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) has gone a long way towards building confidence in its efficacy – but have […]
Boehringer takes on antimicrobial resistance with Evotec, bioMérieux JV
A Franco-German joint venture company – Aurobac Therapeutics – has been formed to try to tackle the rising threat of antimicrobial resistant (AMR) infections. The […]
AstraZeneca agrees $1.3bn deal to buy oncology player TeneoTwo
AstraZeneca has signed a deal to buy US biotech TeneoTwo in a deal worth up to $1.27 billion that will boost its position therapies for […]
The post-Covid New Normal: a golden opportunity for the NHS?
I recently had the pleasure of attending the PING Conference 2022, which had the tagline of ‘The Golden Age for Life Sciences Innovation’. In part, […]
Astellas teams up with UK biotech Mogrify on hearing loss project
Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy regenerative medicine to treat hearing loss caused […]
Partners come on board GSK’s plan for Stevenage life science hub
GSK’s recently-unveiled plan to develop a bioscience cluster close to its main R&D site in Stevenage, UK, has moved closer to fruition, now that the […]
UK adds £175m funding to clinical research recovery drive
The UK government has made an additional £175 million ($212 million) in funding available for its push to make the country a go-to location for […]
StartUp Health takes a multidisciplinary approach to fight type 1 diabetes
David Weingard, chief impact officer of T1D Moonshot and founder of Cecelia Health, tells us how T1D Moonshot aims to break silos and advance type […]
After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome
Two weeks after reporting disappointing results for its lead coeliac disease therapy, 9 Meters Biopharma will draw some comfort from a mid-stage trial of its […]
Medical Informatics and Rare Disease: a bridge between two worlds
Today’s rare disease landscape comprises of around 7,000 different diseases. With a broad and diverse range of symptoms and severities impacting patients around the world, […]
Teva poaches Vertex exec as new head of R&D
Teva chief executive Kare Schultz has lined up the appointment he wants to revitalise the company’s R&D operations, naming Vertex Pharma’s Eric Hughes to the […]
Novartis eyes earlier use of PD-1 drug in oesophageal cancer
Novartis is still waiting for FDA approval of its PD-1/PD-L1 inhibitor latecomer tislelizumab in relapsed oesophageal cancer, but is already planning a move the drug […]
AZ takes aim at BMS’ lead in neoadjuvant NSCLC
Just weeks after Bristol-Myers Squibb claimed an FDA green light for Opdivo as a neoadjuvant therapy for non-small cell lung cancer, AstraZeneca is looking to […]
Blueprint cashes in on the past to build its future
Blueprint Medicines has taken an unusual route to raising cash for its R&D pipeline – selling off some of the royalties from its already-approved medicines […]
Liver injuries prompt clinical hold on Sanofi BTK drug
One of the main assets of Sanofi’s $3.7 billion buyout of Principia Biopharma has run into trouble, after the FDA placed it on partial clinical […]
From trial design for patients to trial design with patients: a key topic at DIA ’22
At the 2022 Drug Information Association (DIA) annual meeting last week, it was inspiring to connect with fellow research and development (R&D) stakeholders, regulators, health […]
Pfizer and Roivant launch autoimmune specialist Priovant
The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer […]
US panel backs Omicron-targeting vaccines for booster campaigns
Future booster campaigns against COVID-19 should include vaccines with a component targeting the Omicron variant of SARS-CoV-2, according to the FDA’s Vaccines and Related Biological […]
Novartis will shed 7% of workforce in restructuring, say reports
A Swiss newspaper has said Novartis’ previously announced restructuring programme could lead to 8,000 axed jobs, including up to 1,400 at its home base in […]
Basilea preps key US filing for MRSA antibiotic ceftobiprole
Basilea Pharmaceutica may finally be able to bring its antibiotic ceftobiprole to the US market – 13 years after its first attempt was turned down […]
Preventing the next pandemic: Learning the lessons
In the first of a three part series, Ben Hargreaves looks at what the odds are of another pandemic arising in our lifetimes and what […]
Study exposes lack of diversity in US cancer trials
Almost half (48%) of cancer clinical trials in the US have no Hispanic or Latin American subjects, and 42% have no black patients, according to […]
GSK hepatitis B hope bepirovirsen heads for phase 3 test
An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 […]
Another Astellas gene therapy hits a safety hurdle
The safety of Astellas’ gene therapy portfolio has been thrust into the spotlight once again, after the FDA placed a clinical hold on a trial […]
Data backs AZ’s Wilson disease drug, but with a question mark
Last year, AstraZeneca reported that a new drug to treat Wilson disease developed by its Alexion rare diseases unit had hit the mark in a […]
Sarepta shares yo-yo as FDA places hold on Duchenne trial
Shares in Sarepta came under pressure after the biotech said it had temporarily halted a clinical trial of its new-generation Duchenne muscular dystrophy candidate, after […]
New countries stockpile antiviral TPOXX as monkeypox outbreak continues
pharmaphorum editor in chief Jonah Comstock talks to Philip Gomez, CEO of Siga Technologies, about how his company’s antiviral drug can play a crucial role […]
Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis
Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for […]
Moderna says COVID booster works against Omicron subvariants
Moderna has reported top-line data suggesting that its COVID-19 booster vaccine candidate stimulates a strong immune response against the Omicron subvariants BA.4 and BA.5, which […]
Moderna facility in UK confirmed, part of 10-year deal with gov’t
Moderna has said it will open a new R&D and manufacturing facility in the UK which could lead to improved access by NHS patients to […]
Merck ups the stakes in pneumococcal jab face-off with Pfizer
Dominance of the pneumococcal vaccine category is a race between Merck & Co and Pfizer, and while the latter is comfortably in front at the […]
Single MRI-based brain scan could diagnose Alzheimer’s disease, says study
Alzheimer’s disease could be diagnosed from a single MRI brain scan, according to a new study by Imperial College London. Using machine learning technology, researchers […]
AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen
Armed with new phase 3 data, AstraZeneca is preparing to file for regulatory approval of eplontersen, an antisense drug for one of the complications of […]
Pfizer takes stake in French Lyme disease jab partner Valneva
Pfizer has acquired an 8.1% stake in French vaccines developer Valneva at a cost of €90.5 million (around $95 million) and rejigged the terms of […]
Evaluate’s Orphan Drug Report 2022
Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the company’s Orphan Drug Report 2022, which highlights […]
Is Merck planning a $30bn-plus move for Seagen?
Speculation that Merck & Co may be preparing a $30 billion takeover bid for Seagen – bolstering its oncology ambitions – has the biopharma community […]
Pharmacy chain Walgreens plans to disrupt clinical trial sector
Walgreens is the latest US retail pharmacy giant to have a go at disrupting the clinical trials industry, with the launch of a new business […]
Biogen waves bye to $217m ALS partnership with Karyopharm
Biogen has ducked out of a four-year-old collaboration with Karyopharm on a drug candidate for the neurodegenerative disease amyotrophic lateral sclerosis that could have been […]
MorphoSys slims down, narrowing its focus to cancer
MorphoSys seemingly inexorable shift into an oncology pure-play has continued with an out-licensing deal for two programmes in the kidney disease and immunology categories to […]
Another amyloid miss in Alzheimer’s as Roche’s crenezumab fails trial
The litany of failed trials of amyloid-targeting drugs for Alzheimer’s disease has added another verse, as Roche concedes that its crenezumab candidate was unable to […]
Boehringer takes option on masked cytokine specialist Trutino
Boehringer Ingelheim must like what it has seen in its two-year-old R&D collaboration with Trutino Biosciences to develop cytokine therapies – it has just taken […]
5th International Cannabinoid-Derived Pharmaceuticals Summit
Over the last half-decade, we have witnessed game-changing developments within the cannabinoid field, driving it into a new era of rigorous research, promising clinical trials […]
FDA’s treatment of China-developed drugs spurs demands for multiregional clinical trials
China’s emergence as an R&D powerhouse means that the country is quickly adding a number of drug candidates to the global pipeline. Despite more treatment […]
Genomics England will move HQ to Canary Wharf’s new biocluster
Canary Wharf’s bid to become a new hub for the life sciences sector in the UK has been given a boost following the decision by […]
EHA: ADC preps filings for Hodgkin lymphoma drug after ph2 readout
ADC Therapeutics is looking to add a second approved antibody-drug conjugate to its portfolio after reporting strong phase 2 results with camidanlumab tesirine (cami) in […]
EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track
Three years after Daiichi Sankyo’s FLR3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial […]
EHA: Vertex, CRISPR build case for gene-editing drug
A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical trial, with an update at the EHA […]
Takeda bolsters data for dengue jab as regulatory reviews roll on
Takeda has reported positive new, long-term results in its pivotal trial of dengue fever vaccine TAK-003 that builds the case for the shot as regulators […]
Relief for GSK as RSV vaccine clears phase 3 test in adults
GSK will start preparations for regulatory filings of its respiratory syncytial virus (RSV) vaccine straight away, after the shot hit the mark in the much-anticipated […]
AI specialist Charm Therapeutics launches with $50m Series A
The UK’s fertile environment for biotechs specialising in artificial intelligence has generated a new player – Charm Therapeutics – which came out of stealth mode […]
Owkin bags $180m BMS alliance for cardiovascular clinical trials
Owkin has enticed another big pharma partner with its artificial intelligence-powered clinical development platform, Bristol-Myers Squibb, which is paying $80 million upfront to tap into […]
Combating antimicrobial resistance with a viable alternative to traditional antibiotics
Antimicrobial resistance (AMR) is an issue of global concern, killing roughly 1.2 million1 people per year and projected to rise to 10 million people by […]
Moderna says new bivalent COVID-19 vaccine tops Spikevax
Moderna’s new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company’s original Spikevax shot in a head-to-head clinical […]
Biogen bolsters pipeline again with Alectos deal
Biogen has added a preclinical-stage drug candidate for Parkinson’s disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a […]
Praxis wields the axe as lead depression drug fails
Shares in Praxis Precision Medicines were in freefall today after the company’s efforts to develop a new therapy for major depressive disorder (MDD) ended in […]
Astellas taps GO’s glycoprotein platform with $783.5m deal
Astellas has become the latest big pharma company to sink some money into immuno-oncology start-up GO Therapeutics, forging an alliance to develop antibodies targeting two […]
Amgen eyes swift move to ph3 for cardiovascular drug olpasiran
Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with […]
GSK bolsters vaccines division with $3.3bn swoop on Affinivax
GlaxoSmithKline has agreed a $3.3 billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that […]
4th RAS-Targeted Drug Development Summit
For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has […]
RhoVac pummelled as lead cancer vaccine fails study
Shares in Swedish biotech RhoVac were down 94% in mid-morning trading today after the company revealed a phase 2b trial of its prostate cancer vaccine […]
GSK said to be close to finding partner for science cluster in UK
GlaxoSmithKline is reportedly close to finding a development partner for a major new investment project in the UK that will see a new bioscience cluster […]
Can technology help diversify clinical trials?
This is the second in a two-part series examining how pharma can embrace the DEI agenda to create more effective medicines through more representative clinical […]
Biotech founder arrested in US amid murder-for-hire investigation
The co-founder of Los Angeles biotech Enochian Biosciences has been arrested in connection with a federal investigation into the murder of a Vermont man in […]
Cumulus puts its digital biomarkers for CNS diseases to the test
Cumulus Neuroscience has started a pair of clinical trials to gauge the value of a panel of physiological and digital biomarkers in tracking the course […]
Why are clinical trials struggling with diversity?
In the diverse world we live in, the products we produce, the services we create and the places we work should be as equally representative. […]
Pfizer’s Arena buyout looks canny, as etrasimod aces phase 3 trials
Pfizer placed a $6.7 billion bet on the outcome of two phase 3 trials of Arena Pharmaceuticals’ etrasimod in ulcerative colitis (UC) when it acquired […]
Second trial opens door for Lilly’s mirikizumab in ulcerative colitis
Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as it waits […]
AbbVie adds to Vraylar data as FDA considers depression use
AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression, as it waits for a decision by […]
Bayer bails on $670m CAR-T partnership with Atara
In February, Atara Biotherapeutics paused enrolment into a trial of a CAR-T cell therapy for mesothelioma after a patient death. Now, its partner Bayer has […]
EU imposes Horizon funding block on UK scientists
UK scientists are being denied from joining the €95 billion Horizon research funding programme as a dispute over the trade border in Northern Ireland gets […]
2nd Integrin-Targeted Drug Development Summit
In collaboration with leading integrin drug developers, including Genentech, 7 Hills Pharma, and Pfizer, the 2nd Integrin-Targeted Drug Development Summit is designed for industry leaders to unite and outline clinical […]
Beckley adds digital element to its psychedelic drug trials
Phase 2 trials of Beckley Psytech’s psychedelic drug candidates will make use of digital technologies for patient monitoring, thanks to a new partnership with Empatica. […]
Moderna’s HIV vaccine prepped for trials in Africa
Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of […]
SwanBio raises $56m for rare neurological disease gene therapy
SwanBio Therapeutics has raised $56 million in a second-round financing that will be used to advance its lead gene therapy candidate for adrenomyeloneuropathy (AMN) into […]
AstraZeneca buys into startup RQ Bio’s COVID antibodies
Brand new UK startup RQ Biotechnology has been thrust into the spotlight after signing a $157 million licensing deal with AstraZeneca for monoclonal antibodies intended […]
Unlocking the potential of healthcare data in research
Health data research in the UK is rapidly evolving, with new capabilities emerging through the rise of hybrid engagement and the accelerated adoption of digital […]
Recent advances in neurological disorders
Considerable scientific progress across neurological diseases and disorders was reported at the recent 74th American Academy of Neurology (AAN) Annual Meeting. What may be important […]
AbbVie and Cugene partner to tackle autoimmune diseases
AbbVie and Cugene have teamed up to research autoimmune diseases and cancer in an exclusive worldwide agreement. The Chicago-based pharma firm, AbbVie, received the option […]
2nd Annual mRNA-Based Therapeutics Summit
Do you want to be part of the largest gathering of mRNA professionals? The 2nd Annual mRNA-Based Therapeutics Summit is returning in-person to Boston this July 26-28. Expect exclusive data from […]
BenevolentAI, AstraZeneca AI-based drug discovery collaboration achieves third milestone
BenevolentAI has discovered a second novel target for idiopathic pulmonary fibrosis (IPF), which AstraZeneca has added to its drug development portfolio, resulting in a milestone […]
Novel drug to tackle inflammatory diseases begins trial
An early-stage drug that is being developed to tackle inflammatory and autoimmune diseases has been approved by the US regulator. Inmagene Pharma’s investigational new drug […]
AstraZeneca, Avillion ‘first-in-class’ combination inhaler shines in Phase 3 trial
An albuterol/budesonide fixed-dose combination rescue medication has been shown to reduce severe exacerbations in patients with asthma for the first time, according to positive Phase […]
GSK, iTeos take stock after Roche’s TIGIT setback
iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a […]
Third positive trial sets up filings for AbbVie’s Rinvoq in Crohn’s
AbbVie’s would-be blockbuster Rinvoq has notched up another positive trial in Crohn’s disease, showing that it can achieve clinical remission over a full year when […]
BMS pays $200m to expand Evotec alliance on protein degraders
Bristol-Myers Squibb’s Celgene unit has clearly been impressed by progress in its four-year-old alliance with Evotec on protein degradation. It’s just paid $200 million to […]
Novo Nordisk forges close ties with biotech VC Flagship
Danish drugmaker Novo Nordisk has traditionally generated its pipeline mainly from internal R&D, but a new alliance with venture capital firm Flagship Pioneering signals another […]
AZ, Sanofi build case for one-shot RSV antibody
A pooled analysis of data for AstraZeneca and Sanofi’s respiratory syncytial virus (RSV) antibody nirsevimab has concluded that the drug is almost 80% effective at […]
Roche’s TIGIT ambitions take another blow
Roche’s anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its […]
Oxurion craters as failed trial cuts its pipeline down to one
Shares in Belgian biotech Oxurion are taking a hammering this morning after it reported that one of its drugs for diabetic eye disease had failed […]
Nykode vaccine shows its worth in cervical cancer trial
Adding Nykode Therapeutics’ VB10.16 vaccine to treatment with Roche’s cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer. The […]
J&J ducks out of Bavarian Nordic vaccine partnerships
Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) […]
PING Conference 2022 – The Golden Age for Life Sciences Innovation
The PING Conference 2022 is back in person this year, with opportunities to network face-to-face with people from right across the life sciences ecosystem. We […]
Curebase bags $40m to develop patient-centric trials platform
Curebase has raised $40 million in second-round financing that will help it run more complex interventional trials for its biopharma clients, according to chief executive […]
AZ bites back at rivals with new Farxiga data in heart failure
AstraZeneca’s SGLT2 inhibitor Farxiga has hit the mark in a phase 3 heart failure trial that brings it back into contention with its main rival […]
How patient-on-a-chip tech could be the future of drug discovery
Testing drug compounds on a chip designed to mimic human organs sounds closer to science fiction than reality, yet the technology already exists and is […]
Pre-Filled Syringes San Francisco Conference 2022
SAE Media Group’s 3rd Annual Conference Pre-Filled Syringes San Francisco September 19 – 20, 2022 | San Francisco, CA, USA ————————————————————————- The pre-filled syringes industry […]
Gilead dives deeper into NK cell therapies with Dragonfly deal
Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics’ TriNKET platform to find […]
Fifth scientist convicted in GSK trade secrets case
A scientist working in Switzerland has become the fifth person to be convicted of attempting to steal trade secrets from pharmaceutical group GlaxoSmithKline in a […]
AstraZeneca plans new US R&D hub as revenues rocket
AstraZeneca has revealed plans to set up a new strategic R&D hub in Cambridge, Massachusetts as it reported a massive increase in first-quarter revenues, driven […]
Novo Nordisk once-weekly insulin clears first phase 3 test
For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying […]
Big pharma vs small diseases: Tackling rare diseases
Rare diseases aren’t as rare as the appellation suggests. For instance, according to the US Government Accountability Office, 30 million Americans have a rare disease, […]
Lilly fires a broadside at Novo Nordisk’s obesity ambitions
Denmark’s Novo Nordisk has been almost single-handedly rebuilding the market for drugs to treat obesity over the last few years with its GLP-1 agonist drugs […]
Google, Sanofi back UK biotech OMass’ $100m second round
OMass Therapeutics has raised an impressive $100 million in a Series B financing that is said to be the largest ever for a UK biotech […]
Readout sets up phase 3 for Valneva/Pfizer’s Lyme disease jab
There’s only one vaccine candidate for tick-borne infection Lyme disease in clinical development – Valneva and Pfizer’s VLA15 – and it has just moved another […]
Cidara and Mundipharma prep filings for antifungal rezafungin
Mundipharma and Cidara Therapeutics have reported the results of a phase 3 trial of their new once-weekly antifungal rezafungin, setting up regulatory filings in the […]
Understanding the microbiome as an ‘overlooked critical organ’
Compared to a ‘critical organ’ that had been largely ignored, companies working to develop microbiome-based therapies believe there is untapped potential in the area. Ben […]
Achieving diversity, equity and inclusion in clinical trials
Making sure clinical trials are diverse and representative of the populations they’re studying isn’t just the right thing to do to promote inclusivity and equity; […]
Nkarta leaps on early CAR-NK data in blood cancers
Shares in Nkarta more than doubled yesterday on the results of early-stage clinical that suggested it could be on to a winner with its natural […]
Implants could transform CAR-T therapy into one-day procedure
CAR-T therapies have revolutionised the treatment of some blood cancers, but are costly as well as time- and resource-intensive. Now, US researchers think one solution […]
iPSC Manufacturing Summit
With iPSCs exhibiting game-changing potential in the bid to develop an off-the-shelf therapy, the brand-new iPSC Manufacturing Summit is the only summit dedicated to solving […]
Roche’s oral SERD giredestrant fails breast cancer trial
Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears […]
TCR-based Therapeutics for Solid Tumors Summit
Are you using TCRs to target solid tumors yet? With Immunocore having achieved commercialization for the first TCR therapy in both the US and EU […]
Next Generation RNA Therapeutics Summit
Are you looking to solve challenges with current RNA therapeutics, such as the degradation of RNA by RNAses, the difficulty of RNA crossing the cell […]
Astellas takes $170m charge as it drops DMD gene therapies
Astellas has said it will book a $170 million impairment charge in its fourth quarter results as a result of a decision to halt the […]
Study of Vicore’s DTx for anxiety in IPF patients gets underway
Sweden’s Vicore Pharma has started a clinical trial of a digital therapeutic (DTx) intended to relieve anxiety in patients with idiopathic pulmonary fibrosis (IPF), a […]
Ampio slumps as FDA delivers knee osteoarthritis shock
Ampio Pharma’s candidate therapy for knee osteoarthritis has been knocked back by the FDA, which will likely now require a new clinical trial of the […]
Financing pushes value of clinical trial tech firm Reify to $4.8bn
Reify Health has completed fourth-round financing that adds $220 million to its cash reserves and pushes its valuation up to a heady $4.8 billion, with […]
BioArctic left in the cold as AbbVie abandons Parkinson’s pact
One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – […]
2nd ARDS Drug Development Summit
Acute Respiratory Distress Syndrome (ARDS) is a growing and concerning unmet medical need with no effective therapeutic, and a serious medical burden in a world […]
CRISPR therapies targeting the next breakthrough in oncology
The potential of CRISPR technology has been a hot topic in the industry ever since it was first developed, but as trials progress further into […]
Moderna unveils first clinical data on bivalent COVID variant booster
Moderna has reported preliminary clinical results with a bivalent version of its COVID-19 vaccine that combines its original version with another targeting the Beta variant, […]
Regeneron seeks CheckMate in immuno-oncology play
Regeneron has agreed an all-cash deal to acquire CheckMate Pharmaceuticals, adding immune activator vidutolimod to its cancer immunotherapy pipeline and ending a barren spell for […]
Thread builds in decentralised trials again with CureClick buy
Just over a year after partnering on a project to accelerate recruitment into decentralised clinical trials (DCTs), Thread and CureClick have decided to formally tie […]
3rd Gamma Delta T Therapies Summit
Join the 3rd Gamma Delta T Therapies Summit to learn and network with 120+ of the world’s leaders including γδT pioneer, Adrian Hayday, and together […]
Breaking into the global pharmaceutical market
In 2022, pharma is truly a global industry, and innovation can come from anywhere. But for small life sciences outside of the USA and Europe, […]
Sarepta DMD rival PepGen files $115m IPO
Just days after dosing its first patient in a Duchenne muscular dystrophy trial, US biotech PepGen has pushed the button on an initial public offering […]
End of the line for BMS, Nektar’s bempegaldesleukin/Opdivo alliance
Four years after Bristol-Myers Squibb paid $1.85 billion upfront to make Nektar’s bempegaldesleukin a companion drug to its cancer immunotherapy Opdivo, the alliance is being […]
AbbVie preps filings for lymphoma bispecific licensed from Genmab
Two years after signing a $3.9 billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to […]
AACR: AbbVie says mid-stage trial backs navitoclax in myelofibrosis
AbbVie’s BCL-2 inhibitor navitoclax has reported phase 2 results in a trial involving rare and hard-to-treat blood cancer myelofibrosis, eyeing an indication not addressed with […]
GSK bolsters cancer pipeline with $1.9bn Sierra Oncology buy
GlaxoSmithKline has agreed a deal to buy Sierra Oncology and its lead drug momelotinib for anaemia associated with the blood cancer myelofibrosis, sending the US […]
Emerging technologies that are changing the way healthcare is delivered in 2022
Wherever you consider the medical industry, you will find several new technologies being used to make new medicines, vaccines, and fight illnesses. The purpose is […]
Gilead cleared to restart trials of CD47 drug magrolimab
Gilead Sciences can restart pivotal trials of its cancer antibody magrolimab – the centre piece of its $4.9 billion acquisition of Forty Seven in 2020 […]
Study finds unexpected prescription influencers in healthcare
Cate Evans, SVP group director, strategy at Havas Media Group, and Nick Lapolla, research director at MedSurvey tell us about a two-phase research study the […]
Innovation across the healthcare system is needed to realise the value of medicines
Janssen’s Catherine Taylor, vice-president, EMEA medical affairs, therapy area strategy, discusses the importance of systemic innovation across the healthcare system to realise the full value […]
Pfizer bulks up in RSV with $525m takeover of ReViral
Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). […]
Merck turns to cardiovascular pipeline for its post-Keytruda future
For some years industry observers have been asking what Merck & Co can do to reduce its reliance on blockbuster cancer immunotherapy Keytruda. Now, it […]
Boehringer plans €25bn R&D spend, fuelled by Jardiance
Boehringer Ingelheim says it is planning to invest a hefty €25 billion ($27 billion) in its pipeline over the next five years, as it reinvests […]
Bluebird sheds a third of its workforce to cut costs
Gene therapy specialist bluebird bio has said 30% of its workforce will lose their jobs, in a bid to conserve cash as it tried to […]
Why VCs fell in love with pharma R&D in 2021
For many years, those inside the pharma industry have been telling the same old story about innovation: pharma is big, slow, and risk averse. Start-ups […]
Cytokinetics’ heart drug omecamtiv strikes out in heart failure trial
Cytokinetics’ hopes of resurrecting cardiac myosin inhibitor omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 […]
Study uncovers new Alzheimer’s genes, links to immune disruption
The largest-ever study of genetics in Alzheimer’s disease patients has identified 42 new genes that appear to be linked to the neurodegenerative disorder. The new […]
Pharma-backed antibiotic fund makes first investments
Two years after it was first proposed and a year after it officially launched, the pharma-backed AMR Action Fund has made its first investments in […]
AXA beefs up life sciences investments with $500m push
Multinational insurance company AXA has launched a new €440 million ($500 million) drive to provide private equity investments in healthcare companies that deepens its interest […]
CMO John Tsai exits, as Novartis starts revamp that aims to save $1bn
Novartis chief executive Vas Narasimhan, already eyeing a possible divestment of generics business Sandoz, has now turned his attention to the rest of the company. […]
NIH funds study to evaluate long-term COVID in children
The National Institutes of Health (NIH) is funding a nationwide study in the US to support research on long-COVID, chronic COVID, or as it’s scientifically […]
Five things to watch as the Biosimilars market heats up in 2022
As pressure mounts on the U.S. Congress and the White House to curtail prescription drug prices, many experts continue to point to biosimilars and their […]
Vertex Pharma makes progress in quest for non-opioid pain drug
The search for an alternative to opioid drugs for pain relief has dragged one for decades, with little success, but Vertex Pharma thinks that could […]
And then there were three; ex-Merck CEO Ken Frazier joins Eikon
The board of Eikon Therapeutics will soon look like Merck & Co’s a few years ago – after the big pharma’s former CEO Ken Frazier […]
CureVac and GSK try again with COVID-19 vaccine
CureVac and GlaxoSmithKline’s first attempt to develop a COVID-19 vaccine was a salutary reminder of the pitfalls in drug development, as the mRNA shot crashed […]
Canary Wharf makes play to become UK life sciences hub
The organisation behind the iconic Canary Wharf development has said it plans to build one of the largest commercial laboratory facilities in Europe as part […]
Amazon gathers Thread in decentralised trials alliance
Amazon’s latest push into the healthcare arena is focusing on one of the top new trends in clinical research – the shift towards decentralised trials. […]
Does the answer to advancing rare disease treatment lie in real-world data?
What do 300 million people have in common? They are living with rare diseases that are defined by their scarcity within the general population. In […]
New blow for ALS pipeline as Biogen and Ionis candidate fails Phase 1 trial
Less than six months after the late-stage failure of tofersen, Biogen and Ionis have suffered further disappointment in the amyotrophic lateral sclerosis (ALS) pipeline after […]
AI tool helps detect leprosy using pictures
Ann Aerts, head of the Novartis Foundation, tells us about AI4Leprosy, a diagnostic assistant researchers developed that helps healthcare workers detect leprosy with over 90% […]
GSK partners LifeMine on fungi-derived medicines
GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely […]
Etrasimod data suggests Pfizer’s $6.7bn gamble on Arena will pay off
It’s only been two weeks since Pfizer closed its $6.7 billion takeover of Arena Pharmaceuticals, and it already has the positive data it was hoping […]
Handover of senior R&D roles at Merck continues, as Roy Baynes exits
Merck & Co’s chief medical officer and head of clinical development Dr Roy Baynes has announced his retirement from the company to take up a […]
Government pledges to work with industry to make UK a genomics leader
With initiatives like The 100,000 Genome Project, the UK has led the world on genomic research. In a bid to maintain that position, the governments […]
With rivals threatening, Argenx scores key myasthenia gravis win
Argenx only recently scored FDA approval for its intravenous anti-neonatal FC receptor (FcRn) antibody Vyvgart for generalised myasthenia gravis (gMG), but is already looking to […]
Using cross-functional teams to develop a product’s value story
Tanya Brinsden, senior VP of operations at ICON Global Medical Communications and Pubs Hub, Jessica Cherian, VP of content and strategic services at ICON Market […]
Ex-Biogen R&D head Sandrock takes the top job at Voyager
Voyager Therapeutics has lost little time in elevating Al Sandrock to the chief executive position, with the appointment coming just a few weeks after he […]
Virtual and augmented reality: Bringing the future to pharma manufacturing
Virtual and augmented reality tools have reached a level of maturity to be utilised across various industries. In this article, Ben Hargreaves asks whether there […]
Welcome to 1st Rare & Genetic Neurodegenerative Drug Development Summit
Neuroscience is arguably the next great frontier in medicine and 2022 dawned with a wave of exhilarating progress for the neurodegenerative drug development community. Eli […]
BMS buys into Volastra’s cancer expertise with $1.1bn alliance
Bristol-Myers Squibb is the first big pharma to strike a deal with Volastra Therapeutics, a start-up that has developed a drug discovery platform based on […]
No room for commercial competition in sustainable pharma
With the healthcare sector accounting for around 4% of global emissions – about the same as a small country – only an ecosystem-wide effort will […]
Think global, act local: rethinking commercialisation models
The global market for life sciences is changing rapidly. Fuelled by technological advancements and a global pandemic, there are more opportunities than ever for companies […]
Biogen finally publishes its phase 3 Aduhelm data
After months of debate about the validity of its phase 3 clinical trials for Alzheimer’s therapy Aduhelm, Biogen has published the results in a peer-review […]
Longer-term data raise prospects for Apellis’ pegcetacoplan
Apellis chances of getting regulatory approval for pegcetacoplan, its drug candidate for sight-robbing disease geographic atrophy (GA), may have been heightened by new follow-up data […]
Amplifying the voices in rare diseases
There are approximately 300 million people around the world living with a rare disease. Yet, until relatively recently, there was limited focus on this heterogenous […]
AbbVie extends Gedeon Richter alliance that gave it Vraylar
AbbVie’s longstanding alliance with Hungarian drugmaker Gedeon Richter has already given it one blockbuster medicine – Vraylar for schizophrenia and bipolar disorder – and the […]
Does the pandemic mark a turning point in vaccine development?
After a period where vaccine development had fallen away, suddenly it is back in the limelight. Investment has flowed back into the sector and Ben […]
Venatorx plans new antibiotic filing after phase 3 readout
Venatorx Pharma has moved a step closer to what has unfortunately become a rare event in pharma – the filing of a new antibiotic designed […]
AbbVie sees bigger role for Qulipta in migraine prevention
AbbVie’s Qulipta has become the first oral drug in the CGRP inhibitor class to show efficacy in chronic migraine prevention in a pivotal trial, setting […]
Welcome to the 2nd Chronic HBV Drug Development Summit
Advance Combination Therapies, Outline Clinical Endpoints & Understand the Immunology Perspective to Achieve Functional Cures for Chronic Hepatitis B. With a tight lens on late […]
Investing in biologics excellence
In little over three decades, advances in biotechnology have noticeably disrupted the development landscape of small molecule drugs. Yet, despite the immense potential of the […]
Scenic Bio raises $31m for genetic modifier platform
18 months after signing its first partnering deal with Genentech, Scenic Biotech has raised $31 million in first-round financing that it will use to take […]
Taking responsibility for changing lives: Sharing data and accelerating access
Is open, responsible research the key to translating quality science into clinical benefit as quickly as possible? We ask the AMRC’s new CEO, Nicola Perrin. […]
Sanofi, Sobi eye filings for once-weekly haemophilia A therapy
Sanofi and Sobi’s haemophilia partnership has been under competitive pressure from new therapies like Roche’s antibody Hemlibra, so the two companies are hoping a new […]
Novartis puts up $1.7bn for Voyager’s gene therapy platform
Voyager Therapeutics has signed another big pharma partner for its TRACER adeno-associated virus (AAV) vector technology, designed to improve the safety of gene therapies, with […]
IWD: Spotlight on women in life sciences
To celebrate International Women’s Day, we speak to design engineer at Envair Technology Darina Shopova; managing director, UK & ROI at Healthcare Business of Merck […]
Moderna targets 15 pathogens in ‘global public health strategy’
Moderna has unveiled plans to start clinical trials of mRNA-based vaccines for 15 infectious diseases that pose the biggest public health risks around the world […]
Astellas’ eyes filings for menopause drug fezolinetant after ph3 win
Astellas looks to be in pole position to bring a new non-hormonal therapy for symptoms of menopause to market, after its candidate fezolinetant cleared a […]
WHO announces international hub for mRNA vaccine training
The World Health Organization (WHO) announced the opening of a global biomanufacturing hub located in South Korea to provide training to low- and middle-income countries […]
Roche starts new four-year trial of Alzheimer’s drug gantenerumab
With prospects of an early, accelerated approval for Roche’s Alzheimer’s disease candidate gantenerumab looking diminished, the drugmaker has launched a new four-year trial in the […]
Olumiant benefits additive to other drugs in severe COVID patients
Eli Lilly and Incyte’s JAK inhibitor Olumiant reduced the risk of death by 13% in hospitalised COVID-19 patients when added to other drugs, according to […]
Stage set for Jardiance to become universal heart failure drug
Boehringer Ingelheim and Eli Lilly have published data for their SGLT2 inhibitor Jardiance in acute heart failure, setting them on course to position the drug […]
One year on: How is the UK’s vision of a future-proof research environment shaping up?
One year ago, a UK-wide vision for the country’s future research landscape promised streamlined processes, and a patient-centred, competitive environment. But how far have we […]
Can psychedelics provide breakthrough in mental health?
There is a growing pipeline of psychedelic therapies and an expanding body of science to suggest that they may be able to provide an alternative […]
Pfizer’s seeks silver lining in failed C. diff vaccine trial
Pfizer’s vaccine for Clostridium difficile (C. diff) looks like it may join a growing list of candidates that have been shelved or delayed, after the […]
AbbVie adds to neuroscience pipeline with $1bn Syndesi buy
Four years after spinning out from Belgium’s UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought by AbbVie for $130 million upfront. The […]
Primary care sites: A new avenue for clinical research
The primary care setting offers huge potential for commercial research. This was, and still is being, demonstrated through the UK’s COVID-19 vaccine research successes. But primary […]
Verily taps Oncimmune tech for ‘long COVID’ study
Alphabet’s Verily Life Science has contracted UK biotech Oncimmune to investigate autoantibodies in people who have developed long-lasting symptoms after COVID-19 infection, a condition known […]
GSK’s halts RSV vaccine trials in pregnant women after pause
It looks like GlaxoSmithKline’s concerns about its respiratory syncytial virus (RSV) vaccine in pregnant women aren’t going to be resolved quickly. After suspending three trials […]
Rare Disease R&D: one step forward, but a long road ahead
With over 40% of all medicines in the pipeline aimed at rare diseases, the future looks positive for increasing the number of treatments available. However, […]
